Othera Initiates Phase I/II Clinical Trial of OT-730 in Ocular Hypertension and Glaucoma
News Sep 16, 2008
Othera Pharmaceuticals, Inc. has announced that it has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma.
The study is a randomized, multi-center, investigator-masked, timolol- and placebo-controlled evaluation of the safety and efficacy of OT-730 in reducing the intraocular pressure in subjects with ocular hypertension or open-angle glaucoma. Subjects will be randomized to one of 0.75% OT-730, 0.5% timolol maleate or placebo.
Differentiation in the glaucoma market for OT-730 derives from an enhanced safety profile within a well-accepted class of marketed drugs. OT-730 is a novel, internally developed next generation topical beta-blocker designed to lower intra-ocular pressure (IOP), the leading risk factor for developing glaucoma.
Beta-blockers as a class are among the most widely-prescribed drugs for glaucoma, but carry label warnings regarding the potential for serious systemic side effects.
In preclinical animal studies, OT-730 demonstrated comparable IOP-lowering efficacy and superior systemic safety to the most-prescribed ocular beta-blocker, timolol maleate. OT-730 is by design an oculoselective drug, having excellent beta-blocking activity in the eye, yet easily metabolized into inert components upon entry into the bloodstream.
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018